Register to join the Nasodine Common Cold trial


Firebrick Pharma is appealing to adult residents in South Australia and Victoria to participate in our clinical trial of Nasodine® Nasal Spray for the common cold.

Participants will be compensated for their time and expenses incurred in the study.

The Phase 3 trial is being conducted at 3 locations

  • Norwood, South Australia
  • Belmont, Victoria
  • Ballarat, Victoria

“Residents of these areas can be among the first in the world to try Nasodine, which in previous clinical trials has been shown to be safe and well-tolerated. This trial seeks to confirm the efficacy of Nasodine as a treatment for the common cold,” said Firebrick Pharma Executive Chairman, Dr Peter Molloy.

The trial is randomised and placebo-controlled, meaning participants have a 50/50 chance of receiving the active nasal spray medicine or a placebo nasal spray.

All trial participants will be compensated for their time. They will only need to attend one appointment and will then continue the nasal spray treatment regime at home or at work over 5 days, and complete a total of 14 days of brief electronic reporting of symptoms using a webapp. Participants will be tested for COVID-19 to ensure they have the common cold and not COVID-19.

People need to have had cold symptoms for less than 36 hours to join the trial. People can also pre-register if they are not yet sick.

All information and registration details are at commoncoldstudy.com